# CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2010

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2010-05-04
- Accepted by EDGAR: May 4, 2010, 16:31 ET
- Period: 2010-03-31
- Accession: 0001193125-10-106601
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000119312510106601/d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000119312510106601/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2010-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2010-01-01 to 2010-03-31 | $23.76bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2010-01-01 to 2010-03-31 | $19.01bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2010-01-01 to 2010-03-31 | $4.75bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2010-01-01 to 2010-03-31 | $1.41bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2010-01-01 to 2010-03-31 | $510.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2010-01-01 to 2010-03-31 | $771.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2010-01-01 to 2010-03-31 | $0.55 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2010-01-01 to 2010-03-31 | $0.56 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2010-01-01 to 2010-03-31 | 1,396,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2010-01-01 to 2010-03-31 | $1.06bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2010-01-01 to 2010-03-31 | $401.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2010-01-01 to 2010-03-31 | $122.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months, 2010-01-01 to 2010-03-31 | $887.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2010-03-31 | $1.05bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2010-03-31 | $17.16bn | us-gaap:AssetsCurrent |
| Total assets | at 2010-03-31 | $61.28bn | us-gaap:Assets |
| Current liabilities | at 2010-03-31 | $12.34bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2010-03-31 | $8.45bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2010-03-31 | $2.40bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2010-03-31 | $515.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2010-03-31 | $35.69bn | us-gaap:StockholdersEquity |

## Market risk

As filed, 289 characters.

As of March 31, 2010, the Company had no derivative financial instruments or derivative commodity instruments in place and believes that its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio, is not material.

## Controls and procedures

As filed, 5,396 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of March 31, 2010, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that occurred during the three months ended March 31, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

See Item 3 of Part I to 2009 Form 10-K for disclosure relating to material pending legal proceedings. Set forth below is a summary of material developments involving material pending legal proceedings that occurred subsequent to the filing of our 2009 Form 10-K.

### I. Legal Proceedings

1\. In August 2009, the Company was notified by the FTC that it is conducting a non-public investigation under the Federal Trade Commission Act into certain of the Company’s business practices. In March 2010, the Company learned that various State Attorneys General offices and certain other government agencies are conducting a multi-state investigation of the Company regarding issues similar to those being investigated by the FTC. At this time, there are 24 states, the District of Columbia, and the County of Los Angeles, are known to be participating in this multi-state investigation. The Company is cooperating in these investigations and is producing documents and other information on a rolling basis. The Company is not able to predict with certainty the timing or outcome of these investigations. However, it remains confident that its business practices and service offerings (which are designed to reduce health care costs and expand consumer choice) are being conducted in compliance with the antitrust laws.

2\. In January 2010, the Company received a subpoena from the OIG in connection with an investigation of possible false or otherwise improper claims for payment under the Medicare and Medicaid programs. The subpoena requests retail pharmacy claims data for “dual eligible” customers (i.e., customers with both Medicaid and private insurance coverage), information concerning the Company’s retail pharmacy claims processing systems, copies of pharmacy payor contracts and other documents and records. Further, in March 2010, the Company received a subpoena from the OIG requesting information about programs under which the Company has offered customers remuneration conditioned upon the transfer of prescriptions for drugs or medications to our pharmacies in the form of gift cards, cash, non-prescription merchandise or discounts or coupons for non-prescription merchandise. The subpoena relates to an investigation of possible false or otherwise improper claims for payment under the Medicare and Medicaid programs. The Company is cooperating with both of these requests for information and intends to produce responsive documents on a rolling basis. The Company cannot predict with certainty the timing or outcome of any reviews by the government of such information.

### II. Environmental matters

Item 103 of SEC Regulation S-K requires disclosure of certain environmental legal proceedings if management reasonably believes that the proceedings involve potential monetary sanctions of $100,000 or more. The Company has, within the last year, received notices of violation and information requests from governmental authorities regarding environmental compliance matters in California and Connecticut, which have the potential to exceed this threshold. The Company is currently working with governmental authorities in both states to resolve alleged instances of noncompliance with applicable regulations, and responding to outstanding requests for information. The ultimate outcome of these matters cannot be determined at this time.

### Part II Item 2

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased during the three months ended March 31, 2010, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2009 Repurchase Program.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| January 1, 2010 through January 31, 2010 | — | $— | — | $1,500,000,393 |
| February 1, 2010 through February 28, 2010 | 8,840,497 | 33.77 | 8,840,497 | 1,201,456,810 |
| March 1, 2010 through March 31, 2010 | 16,841,201 | 34.92 | 16,841,201 | 613,362,072 |

33

### Part II Item 6

### Exhibits

Filed May 4, 2010.
Source: SEC EDGAR, the filing index for accession 0001193125-10-106601. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
